15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Travere Therapeutics Inc, 10 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $25.00 to $70.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $53.25 sits 6% below the current $56.72. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.40 next quarter toward $4.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy1083%
Hold217%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Travere Therapeutics Inc.
As of Jul, 10 of 12 firms rate TVTX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TVTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.40
Range $-0.95 – $1.11 · 8 analysts · -32% YoY
Next period, 8 analysts expect Travere Therapeutics Inc to earn $0.40 a share (range $-0.95 – $1.11), versus $0.59 a year earlier. Full-year consensus is $1.88, growing to $4.77 the year after.
REVENUE · NEXT QUARTER
$182.1M
Range $146.2M – $227.0M · 8 analysts · +10% YoY
Revenue is expected to reach $182.1M (range $146.2M – $227.0M), +10.5% year-over-year. Full-year consensus is $696.0M, rising to $963.9M next year.
Top analysts covering Travere Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TVTX.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$53.00-6.6% to target
Overall win rate
46%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #107
Buy
$30.00-47.1% to target
Overall win rate
44%
+ Follow
#3
Laura Chico
Wedbush · Rank #122
Buy
$61.00+7.5% to target
Overall win rate
40%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$70.00+23.4% to target
Overall win rate
43%
+ Follow
#5
Greg Harrison
Scotiabank · Rank #177
Buy
$31.00-45.3% to target
Overall win rate
38%
+ Follow
TVTX stock forecast FAQ
What is TVTX's average 12-month price target?+
The 12 analysts with a live target average $53.25 for Travere Therapeutics Inc over the next 12 months, ranging from a $70.00 high to a $25.00 low.
Is TVTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 10 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TVTX?+
The Street-high target is $70.00 (Citigroup), and the Street-low is $25.00 (Stifel). The average of all 12 active targets is $53.25.
How many Wall Street analysts cover TVTX?+
12 analysts have an active rating on Travere Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering TVTX?+
Among analysts who currently cover TVTX, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $53.00 target.
What is Travere Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.40 per share (range $-0.95 – $1.11) across 8 analysts. Full-year EPS is projected at $1.88, rising to $4.77 the following year.
How much revenue is Travere Therapeutics Inc expected to report next quarter?+
Consensus revenue is $182.1M (range $146.2M – $227.0M). Full-year revenue is projected at $696.0M, growing to $963.9M next year.
Have analysts been upgrading or downgrading TVTX lately?+
As of Jul, 10 of 12 firms rate TVTX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TVTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
